HOUSTON and VANCOUVER, Feb. 10,
2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V:
EPI), a pharmaceutical company focused on developing novel
therapies for the treatment of prostate cancer, announced today
that several abstracts on ESSA's lead clinical candidate, EPI-7386,
have been selected for presentation at upcoming medical and
scientific symposia. These presentations will provide further
preclinical characterization of EPI-7386 including new preclinical
data regarding safety studies, gene expression and combination data
with antiandrogens.
2020 American Society of Clinical Oncology Genitourinary
Cancers Symposium
Title: IND Candidate EPI-7386 as an N-terminal Domain
Androgen Receptor Inhibitor in Development for the Treatment of
Prostate Cancer
Abstract
#:
|
142
|
Presenter:
|
Dr. Ronan Le
Moigne
|
Session
Title:
|
Prostate
Cancer
|
Poster
Board:
|
F22
|
Date:
|
Thursday, February
13, 2020
|
Time:
|
11:30am – 1:00pm
PST
|
Location:
|
Moscone West
Building, San Francisco, CA
|
American Association for Cancer Research Special Conference
on Advances in Prostate Cancer Research
Title: The N-terminal Domain Inhibitor of the
Androgen Receptor, EPI-7386, Targets Full Length and Splice Variant
Driven Pathways
Presenter:
|
Dr. Nan Hyung
Hong
|
Poster
Session:
|
B
|
Date:
|
Saturday, March 14,
2020
|
Time:
|
12:30pm – 3:00pm
MST
|
Location:
|
Grand Hyatt Denver,
Denver, CO
|
2020 American Urological Association Annual Meeting
Title: The Preclinical Characterization and Development
of EPI-7386, an N-terminal domain androgen receptor inhibitor, for
the treatment of prostate cancer
Abstract
#:
|
20-6346
|
Presenter:
|
Dr. Ronan Le
Moigne
|
Session
Title:
|
Prostate Cancer:
Advanced IV
|
Moderated
Poster:
|
MP79
|
Date:
|
Monday, May 18,
2020
|
Time:
|
9:30am – 11:30am
EST
|
Location:
|
Walter E. Washington
Convention Center, Washington, D.C.
|
About ESSA Pharma Inc.
ESSA is a pharmaceutical
company focused on developing novel and proprietary therapies for
the treatment of castration-resistant prostate cancer in patients
whose disease is progressing despite treatment with current
therapies. ESSA's proprietary "aniten" compounds bind to the
N-terminal domain of the androgen receptor ("AR"), inhibiting AR
driven transcription and the AR signaling pathway in a unique
manner which bypasses the drug resistance mechanisms associated
with current anti-androgens. The Company is currently progressing
IND-enabling studies and expects to file an IND with the U.S. Food
and Drug Administration ("FDA") for EPI-7386 in the first calendar
quarter of 2020. For more information, please visit
www.essapharma.com or follow us on Twitter under
@ESSAPharma.
About Prostate Cancer
Prostate cancer is the
second-most commonly diagnosed cancer among men and the fifth most
common cause of male cancer death worldwide (Globocan, 2018).
Adenocarcinoma of the prostate is dependent on androgen for tumor
progression and depleting or blocking androgen action has been a
mainstay of hormonal treatment for over six decades. Although
tumors are often initially sensitive to medical or surgical
therapies that decrease levels of testosterone, disease progression
despite castrate levels of testosterone generally represents a
transition to the lethal variant of the disease, mCRPC, and most
patients ultimately succumb to the illness. The treatment of mCRPC
patients has evolved rapidly over the past five years. Despite
these advances, additional treatment options are needed to improve
clinical outcomes in patients, particularly those who fail existing
treatments including abiraterone or enzalutamide, or those who have
contraindications to receive those drugs. Over time, patients with
mCRPC generally experience continued disease progression, worsening
pain, leading to substantial morbidity and limited survival rates.
In both in vitro and in vivo animal studies, ESSA's novel approach
to blocking the androgen pathway has been shown to be effective in
blocking tumor growth when current therapies are no longer
effective.
Forward-Looking Statement Disclaimer
This release contains certain information which, as presented,
constitutes "forward-looking information" within the meaning of the
Private Securities Litigation Reform Act of 1995 and/or applicable
Canadian securities laws. Forward-looking information involves
statements that relate to future events and often addresses
expected future business and financial performance, containing
words such as "anticipate", "believe", "plan", "estimate",
"expect", and "intend", statements that an action or event "may",
"might", "could", "should", or "will" be taken or occur, or other
similar expressions and includes, but is not limited to, statements
regarding presentations with respect to the preclinical
characterization of EPI-7386, the preparation and expected timing
of an IND filing with the FDA for EPI-7386, a Phase 1 study of
EPI-7386, a combination study of EPI-7386 and other statements
surrounding the Company's clinical evaluation of EPI-7386.
Forward-looking statements and information are subject to
various known and unknown risks and uncertainties, many of which
are beyond the ability of ESSA to control or predict, and which may
cause ESSA's actual results, performance or achievements to be
materially different from those expressed or implied thereby. Such
statements reflect ESSA's current views with respect to future
events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by ESSA as of the date of such statements,
are inherently subject to significant medical, scientific,
business, economic, competitive, political and social uncertainties
and contingencies. In making forward looking statements, ESSA may
make various material assumptions, including but not limited to (i)
the accuracy of ESSA's financial projections; (ii) obtaining
positive results of clinical trials; (iii) obtaining necessary
regulatory approvals; and (iv) general business, market and
economic conditions.
Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein
and in ESSA's Annual Report on Form 20-F dated December 19, 2019 under the heading "Risk
Factors", a copy of which is available on ESSA's profile on the
SEDAR website at www.sedar.com, ESSA's profile on EDGAR at
www.sec.gov, and as otherwise disclosed from time to time on ESSA's
SEDAR profile. Forward-looking statements are made based on
management's beliefs, estimates and opinions on the date that
statements are made and ESSA undertakes no obligation to update
forward-looking statements if these beliefs, estimates and opinions
or other circumstances should change, except as may be required by
applicable Canadian and United
States securities laws. Readers are cautioned against
attributing undue certainty to forward-looking statements.
Neither the TSXV nor its Regulation Service Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this release.
View original
content:http://www.prnewswire.com/news-releases/essa-pharma-announces-multiple-abstracts-accepted-for-presentation-at-upcoming-medical-and-scientific-symposia-301002315.html
SOURCE ESSA Pharma Inc